pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
235
stories
Jul 28, 26
GSK shares rise as $2.5B cost-cutting plan unveiled
biospace
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 28, 26
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 25, 26
Anthropic’s life science plans; Novartis CEO on China deals; and more
endpoints
Jul 24, 26
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 22, 26
AI data becomes sticking point in biopharma dealmaking
biospace
Jul 21, 26
Agios scraps sickle cell drug
biopharma dive
Jul 21, 26
Novartis CEO says latest China deals are just following the science
endpoints
Jul 21, 26
Novartis climbs on upbeat drug sales as key readouts loom
biopharma dive
Jul 21, 26
STAT+: Anthropic deepens work with rare disease drugs
stat
Jul 21, 26
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 21, 26
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
Jul 20, 26
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 17, 26
Jasper gets a lifeline in merger with immune drugmaker Kira
biopharma dive
Jul 17, 26
Dimerix buys a kidney injury drug; Arpeggio appears to be winding down
endpoints
Jul 17, 26
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
biopharma dive
Jul 17, 26
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
fiercebiotech
Jul 16, 26
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
Celcuity wins approval for breast cancer drug Revtorpyk
endpoints
Jul 13, 26
STAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and more
stat
Jul 10, 26
STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
stat
Jul 9, 26
STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
stat
← prev
page 6 of 8
next →
